FRANKFURT, Nov. 18, 2021 (GLOBE NEWSWIRE) — Farmako GmbH, an established pharmaceutical wholesaler with a focus on cannabinoid therapy, has imported medical cannabis extracts from Poland for the German market for the first time. The extracts are produced according to the highest standards by the EU GMP-certified cannabis company Pharmacann Polska Sp. Z oo.
Farmako and Pharmacann Polska Sp. Z oo, EU GMP-certified cannabis company based in Poland and part of the PHCANN International Group, have reached an important milestone in their cooperation and have carried out the first import of medical cannabis extracts from Poland to Germany. This import is the first of its kind, and Farmako and PHCANN International have come a long way together to make it possible and thus to open deliveries from Poland to Germany as the largest European cannabis market.
The extracts, which are now on the market under the Farmako brand, are produced by PHCANN International companies. Production takes place with selected hybrid varieties that are grown indoors under GACP – EU GMP conditions and completely without the use of pesticides and extracted and manufactured according to the highest standards and under strict quality control in the EU GMP-certified production facility.
With the launch of the extracts, Farmako is strengthening its position as a medical cannabis supplier with a comprehensive portfolio – from flowers and extracts to isolates to test kits for cannabis identity verification.
“‘Against all odds’ – we have to say that with a touch of self-irony. It took a lot longer than planned and expected to bring the products to market, and it was not an easy path, but we all worked hard to Our partner PHCANN International has shown impressive persistence, but above all a very high level of professionalism. The medical cannabis market in Germany has changed and it is no longer just a matter of delivering the product, especially when it comes to flowers , where there is already a tendency towards oversupply. Together with PHCANN International we want to work on products at competitive and attractive prices, especially to promote extracts as an essential component of cannabis therapy – not only for self-payers and private patients, but for all patients ” , says Katrin Eckmans, managing director of Farmako GmbH.
The German medical cannabis market is now characterized by a large number of manufacturers and dealers who offer a wide variety of flower products. Often times, the same products are sold under different brands and names, which can be confusing for doctors and patients. Extracts offer an alternative here, as they have a standardized cannabinoid content and thus enable controlled and constant medication. However, the market for cannabis extracts is still small, and its market growth has so far been hampered by very high prices, which discourages patients, doctors and health insurance companies. Farmako would like to change this and now offer products at significantly lower prices.
Furthermore, Farmako recently signed a new wholesale agreement for its THC test kits with a leading cannabis manufacturer who will offer the test kits together with its own cannabis products, which underlines Farmako’s position as a reliable industrial partner.
Further details on Famako’s products are available to qualified personnel
made available in the closed department.
As a GDP-certified pharmaceutical wholesaler with a focus on medical cannabis, Farmako would like to enable reliable cannabinoid therapy for all patients with a high level of complaints, as well as providing the best possible support for doctors and pharmacists in their everyday lives: through fair prices, reliable product quality and delivery capability as well efficient service. The company has been selling medical cannabis products to pharmacies in Germany since March 2019 and also has the necessary licenses in Great Britain. Farmako is a 100% subsidiary of the Agra Ventures Ltd group.
More information at: www.farmako.de
About PHCANN International
PHCANN International is a pharmaceutical company with international standards in the manufacture of cannabis-based medicinal extracts and other pharmaceutical dosage forms. Based on market experience from Israel, Canada and the USA, the group’s mission is to ensure the availability of pharmaceutical products based on natural cannabis while maintaining strictly controlled pharmaceutical quality and establishing knowledge about the use of medicinal cannabis.
More information at: www.phcann.pl.
About Agra Ventures
Agra Ventures is a growth-oriented and diversified company with a focus on the international cannabis industry. The group is dedicated to the cultivation, distribution and marketing of high quality cannabis and cannabis-infused products worldwide. The Agra Ventures Group in Canada includes Boundary Bay Cannabis, one of the largest cannabis greenhouse facilities with a focus on the cost-optimized cultivation of highly potent cannabis in Delta, BC. Farmako GmbH, GDP-certified wholesaler based in Frankfurt, has been a reliable supplier of medical cannabis in Germany since 2019.
More information at: www.agraventures.com
Press contact: email@example.com